- Home
- QTRX
as 07-26-2024 4:00pm EST
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory, Homebrew - Custom Assay Development, and Uman NF-Light.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BILLERICA |
| Market Cap: | 551.1M | IPO Year: | 2017 |
| Target Price: | $27.00 | AVG Volume (30 days): | 426.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.82 - $29.70 | Next Earning Date: | 08-05-2024 |
| Revenue: | $125,978,000 | Revenue Growth: | 20.64% |
| Revenue Growth (this year): | 18.44% | Revenue Growth (next year): | 18.62% |
Stock Insider Trading Activity of Quanterix Corporation (QTRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| OLSON LAURIE J | QTRX | Director | May 14 '24 | Sell | $16.98 | 1,500 | $25,470.00 | 13,738 | SEC Form 4 |
| OLSON LAURIE J | QTRX | Director | Apr 1 '24 | Sell | $23.50 | 1,000 | $23,500.00 | 15,238 | SEC Form 4 |
| OLSON LAURIE J | QTRX | Director | Feb 14 '24 | Sell | $24.35 | 1,500 | $36,525.00 | 15,238 | SEC Form 4 |
| OLSON LAURIE J | QTRX | Director | Jan 2 '24 | Sell | $26.91 | 1,000 | $26,910.00 | 16,738 | SEC Form 4 |
| OLSON LAURIE J | QTRX | Director | Nov 14 '23 | Sell | $21.89 | 1,500 | $32,835.00 | 13,791 | SEC Form 4 |
Latest Quanterix Corporation News
QTRX Breaking Stock News: Dive into QTRX Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Quanterix to Participate at the Scotiabank Healthcare 1x1 Day
Yahoo Finance Video
2 months ago
FDA panel votes to recommend Eli Lilly's Alzheimer's drug
GlobeNewswire
2 months ago
Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis
Reuters
2 months ago
California seeks company profits in Big Oil climate lawsuit
USA TODAY
2 months ago
S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead
GlobeNewswire
2 months ago
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Business Wire
2 months ago
Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
GlobeNewswire
2 months ago
Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research
Compare QTRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QTRX Quanterix Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.